purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation jnj earnings call period ending march image source motley fool johnson johnson jnj q earnings callapr etcontents prepared remark question answer call participant prepared remark operatorgood morning welcome johnson johnson firstquarter earnings conference call operator instruction call recorded anyone objection may disconnect time operator instruction would like turn conference johnson johnson may beginjessica moore vice president investor relation hello everyone jessica moore vice president investor relation johnson johnson welcome company review first quarter business result fullyear financial outlook logistics get detail reminder find additional material including today presentation associated schedule investor relation section johnson johnson website investorjnjcom please note presentation contains forwardlooking statement regarding among thing company future operating financial performance market position business strategy cautioned rely forwardlooking statement based current expectation future event using information available date recording subject certain risk uncertainty may cause company actual result differ materially projected description risk uncertainty factor found sec filing including form k available investorjnjcom sec websiteadditionally several product compound discussed today developed collaboration strategic partner licensed company slide acknowledges relationship moving today agenda start reviewing first quarter sale pl result corporation well highlight related two business joe wolk cfo provide additional business financial commentary sharing overview cash position capital allocation priority guidance remaining time available question joaquin duato chairman ceo well jennifer taubert john reed tim schmid innovative medicine med tech leader joining u qa ensure provide enough time address question anticipate webcast last approximately minute unless otherwise stated financial result guidance highlighted today reflect continuing operation johnson johnson furthermore percentage quoted represent operational result therefore exclude impact currency translation turning first quarter sale result worldwide sale billion first quarter sale increased growth yous decline outside yous excluding impact covid vaccine operational sale growth worldwide outside yous sale growth europe excluding covid vaccine turning earnings quarter net earnings billion diluted earnings per share versus basic loss per share year ago excluding aftertax intangible asset amortization expense special item period adjusted net earnings quarter billion adjusted diluted earnings per share representing increase respectively compared first quarter operational basis adjusted diluted earnings per share increased comment business sale performance quarter beginning innovative medicine worldwide innovative medicine sale billion increased growth yous decline outside yous excluding impact covid vaccine operational sale growth worldwide outside yous innovative medicine growth driven key brand continued uptake recently launched product nine asset delivering doubledigit growth continue drive strong sale growth across multiple myeloma portfolio darzalex growth primarily driven share gain point across line therapy point frontline setting quarter disclosing tecvayli sale previously reported oncology sale achieved million quarter compared million first quarter last year reflecting strong launch relapsed refractory setting carvykti achieved sale million compared million first quarter last year driven continued capacity expansion manufacturing efficiency strong demand sequential growth roughly flat due phasing continue anticipate quarteroverquarter growth acceleration back half year oncology growth driven continued strong uptake talvey gprcd bispecific rybrevant bispecific antibody nonsmall cell lung cancer also oncology erleada continues deliver strong growth primarily driven share gain growth pulmonary hypertension driven favorable patient mix share gain market growth opsumit uptravi reminder favorable patient mix driver q q therefore still anticipate growth expect lap dynamic beginning q within immunology saw sale growth tremfya driven market growth share gain stelara growth driven market growth share gain ibd partially offset unfavorable patient mix yous expected share loss pso psa anticipate continued volume growth largely offset price decline move toward biosimilar entry neuroscience spravato growth continues driven share gain additional market launch total innovative medicine sale growth partially offset unfavorable patient mix xarelto anticipate continuing throughout year well decrease imbruvica due competitive pressure partially offset stocking dynamic yous finally worth noting distribution right remicade simponi europe returned q turn attention medtech worldwide medtech sale billion increased growth yous outside yous quarter worldwide medtech growth negatively impacted approximately basis point due fewer selling day disproportionately impacting orthopaedics cardiovascular previously referred interventional solution electrophysiology delivered doubledigit growth strong growth region performance driven global procedure growth new product uptake commercial execution onetime inventory build asia pacific impacting worldwide growth approximately basis point addition abiomed delivered growth driven continued strong adoption impella impella rp technology orthopaedics growth includes onetime revenue recognition timing change related certain product across platform yous positively impacting worldwide growth approximately basis point reminder orthopaedics overindexed impact reduced selling day quarter strong performance hip knee driven procedure recovery growth new product commercial execution trauma spine negatively impacted competitive pressure core trauma impacted weatherrelated softness yous growth surgery driven primarily procedure recovery strength biosurgery wound closure portfolio partially offset competitive pressure china volumebased procurement energy endocutters contact lens declined driven yous stocking dynamic partially offset strong performance acuvue oasys day family product worldwide growth negatively impacted basis point due blink divestiture q surgical vision grew driven tecnis eyhance monofocal intraocular lens partially offset china vbp turning consolidated statement earnings first quarter would like highlight noteworthy item changed compared quarter last year cost product sold margin leveraged basis point primarily driven lower covid supply networkrelated exit cost selling marketing administrative margin deleveraged basis point driven primarily timing marketing investment innovative medicine business continue invest strategically research development competitive level investing billion sale quarter invested billion sale innovative medicine increase investment driven continued pipeline progression medtech rd investment billion sale slight decrease driven phasing interest income million first quarter compared million expense first quarter increase income driven lower average debt balance higher interest rate earned cash balance income expense income million first quarter compared expense billion first quarter change primarily due billion charge related talc settlement proposal recorded first quarter regarding tax quarter effective tax rate versus period last year primarily driven tax benefit talc settlement proposal recorded first quarter excluding special item effective tax rate versus period last year encourage review upcoming first quarter q filing additional detail specific taxrelated matter lastly direct attention box section slide also provided income tax net earnings earnings per share adjusted exclude impact intangible amortization expense special item let u look adjusted income tax segment first quarter adjusted income tax enterprise percentage sale increased primarily driven increase nonallocated interest income innovative medicine medtech margin remaining relatively flat year year comparing fourth quarter full year innovative medicine medtech adjusted income tax margin improved concludes sale earnings portion call pleased turn joe joe wolk executive vice president chief financial officer thank jessica hello everyone heard solid financial start complemented sustained momentum within innovative medicine medtech pipeline marked significant regulatory clinical milestone delve segment highlight quarter want touch upon important announcement made enhance competitive positioning earlier month announced definitive agreement acquire shockwave medical johnson johnson long history addressing cardiovascular disease innovative medicine medtech business acquisition shockwave leading intravascular lithotripsy ivl technology provide u unique opportunity impact coronary artery peripheral artery disease two highestgrowth innovationoriented segment within cardiovascular intervention addition adjacent cardiovascular business also consistent strategy becoming bestinclass medtech company first quarter also expanded innovative medicine portfolio completion ambrx acquisition promising pipeline adc platform ambrx strengthen oncology portfolio ability deliver enhanced precision biologics treat cancer move segment highlight quarter jessica previously shared growth innovative medicine continues driven momentum key brand adoption new product quarter hit several regulatory clinical target key delivering longerterm growth starting oncology multiple myeloma received fda approval positive chmp opinion carvykti patient received least one prior therapy making bcmatargeting treatment available patient secondline setting also received biweekly dosing approval fda tecvayli approved bcmatargeting bispecific antibody provides patient dosing flexibility finally submitted application ema regulatory approval darzalexbased quadruple therapy granted yous priority review fda addition made significant step forward treatment patient egfrmutated nonsmall cell lung cancer quarter received fda approval rybrevant combination chemotherapy firstline treatment patient locally advanced metastatic nonsmall cell lung cancer egfr exon insertion mutation approval based data phase papillon study also received priority review fda submitted filing ema rybrevant combination lazertinib firstline treatment option adult patient locally advanced metastatic egfr mutation nonsmall cell lung cancer priority review filing ema supported data landmark phase mariposa study turning immunology portfolio submitted supplemental biologics license application fda seeking approval tremfya treatment adult moderate severe ulcerative colitis looking forward presenting data phase quasar study evaluating tremfya patient ulcerative colitis digestive disease week may also significantly advanced pipeline important data readout including positive topline result frontier study demonstrating jnj first investigational targeted oral peptide maintain skin clearance moderate severe plaque psoriasis one year nipocalimab also delivered positive topline result phase phase study adult sjogrens disease myasthenia gravis respectively also received fda breakthrough designation treatment hdfn hemolytic disease fetus newborn fast track designation fnait rare potentially fatal blood disorder infant looking ahead expect upcoming data readout erleada localized prostate cancer well aticaprant seltorexant major depressive disorder also expect phase result combination therapy jnj psoriatic arthritis well pivotal data tar nonmuscle invasive bladder cancer presented american urological association annual meeting may lastly excited present phase tremfya crohn disease data well subcu data rybrevant upcoming medical meeting medtech notable highlight first quarter include significant advancement across cardiovascular portfolio pulsed field ablation received ce mark approval varipulse based month inspire study demonstrated patient achieved freedom recurrence zero primary adverse event filed yous approval varipulse based admire study showed pilot phase patient achieved acute success remaining free atrial arrhythmia reoccurrence one year also submitted ce mark filing dual energy smarttouch sf catheter provide physician optionality rf psa energy source one catheter began enrollment patient pivotal trial evaluating laminars left atrial appendage elimination device reduce risk stroke patient nonvalvular atrial fibrillation latebreaking danger shock study presented american college cardiology conference simultaneously published new england journal medicine confirmed routine use abiomeds impella cp patient heart attack stemi cardiogenic shock reduced day mortality vision launched tecnis puresee nextgeneration presbyopiacorrecting lens cataract patient emea also presented new data presbyopia correcting iol tecnis odyssey american society cataract refractive surgery april looking ahead continue advance electrophysiology pipeline full yous market release qdot micro catheter yous commercial launch abiomeds impella rp flex smartassist well submission impella ecp within robotic surgery pipeline track submit investigational device exemption fda ottava second half turning financials starting cash capital allocation ended first quarter billion cash marketable security billion debt net debt position billion pleased free cash flow generation first quarter approximately billion first quarter included consumer health business cash flow also first quarter incurred elevated payment level made furtherance achieving responsible final comprehensive resolution talc litigation continue maintain healthy balance sheet strong credit rating underscoring strength johnson johnson financial position ability execute capital allocation priority innovation continues main priority company demonstrated industryleading rd spend first quarter invested billion research development sale also remain committed returning capital directly shareholder dividend appreciate value investor place dividend pleased announce morning board director authorized increase marking nd consecutive year dividend increase stated previously disciplined approach inorganic growth prioritize acquisition strategically fit present meaningful longterm growth opportunity evidenced pending transaction adding profitable commercialized portfolio shockwave technology highgrowth market well robust pipeline discus fullyear guidance excludes recently announced acquisition shockwave previously communicated assume closing transaction take place midyear time update guidance reflect expected dilution adjusted earnings per share approximately per share driven financing cost based result delivered first quarter tightening range increasing midpoint fullyear operational sale adjusted operational eps guidance expect operational sale growth full year range billion billion increasing midpoint million reminder sale guidance continues exclude impact covid vaccine sale know speculate future currency movement last quarter utilized euro spot rate relative yous dollar last week euro spot rate modest strengthening yous dollar also experienced handful currency result estimate negative fullyear foreign currency impact million resulting estimated reported sale growth compared midpoint billion midpoint consistent last quarter guidance maintaining element guidance provided january earnings call exception two item increasing interest income range million million also tightening range adjusted operational earnings per share guidance increasing midpoint reflecting yearonyear growth predicting impact currency movement utilizing recent exchange rate previously referenced reported adjusted earnings per share year estimate negative foreign exchange impact per share result reported adjusted earnings per share remains unchanged reflecting growth versus provide guidance segment quarterly basis continue expect qualitative consideration provided january earnings call remain intact anticipate innovative medicine sale growth slightly stronger first half year compared second half given anticipated entry stelara biosimilars europe midyear medtech expect operational sale growth relatively consistent throughout year looking ahead many important catalyst pipeline drive meaningful near longterm growth across innovative medicine medtech look forward advancing pipeline segment deliver innovative treatment solving complex health challenge would possible without employee around world appropriate turning question recognize thank colleague continued hard work commitment dedication patient pleased joined joaquin jennifer john tim qa kindly ask kevin provide instruction initiate portion call question answer operatorthank operator instruction first question today coming terence flynn morgan stanley line liveterence flynn morgan stanley analyst great thanks much taking question maybe twopart myeloma first carvykti wondering could elaborate phasing comment impacted sale quarter secondly tecvayli think growth product look like somewhat flattish last couple quarter wondering talvey impact think franchise back half year maybe could provide highlevel commentaryjoaquin duato chairman chief executive officer thank terence question go specific question carvykti tecvayli talvey multiple myeloma franchise let share reflection quarter entering position strength particularly encouraged performance strategic platform one going drive growth second half decade innovative medicine darzalex tremfya erleada grew specifically tremfya sale psoriasis psoriatic arthritic indication stelara high expectation brand ulcerative colitis data presented digestive disease week week also data crohn disease presented also year continue see increased demand new product launch spravato tecvayli talvey carvykti carvykti week ago receiving fda approval move second line setting let move medtech demonstrated strong performance across cardiovascular electrophysiology abiomed made significant progress psa portfolio also delivered several important capital allocation milestone q investing heavily rd raising dividend nd consecutive year closing ambrx acquisition announcing planned acquisition shockwave medical heard joe prepared remark continue make progress achieving responsible final comprehensive resolution talc litigation overall proud performance quarter term solid financial also numerous pipeline advancement solid start year put u position strength also sustained progress give u give great confidence achieving longterm growth goal operational sale compounded annual growth rate overall give great confidence future johnson johnson jennifer question terence carvykti tecvayli talveyjennifer taubert executive vice president worldwide chairman innovative medicine well thanks joaquin also quick shoutout big thanks innovative medicine colleague around world delivering adjusted operational growth definitely abovemarket growth quarter strength really across core launch core launch brand nine brand achieving doubledigit growth actually include talvey mix strong pipeline progress joaquin noted also announcement closing acquisition ambrx really add key another key pipeline asset u well key technology help u adc really strong quarter way around respect question specifically multiple myeloma carvykti talvey multiple myeloma continues true stronghold u significant performance growth across board asset quarter start real quickly darzalex growth predominantly growth coming frontline setting also noted perseus data filed offer u additional expansion frontline carvykti growth versus first quarter strong demand adcom united state result unanimous recommendation approval subsequent end quarter approval carvykti line two plus think bodes well know always question expanding capacity given strength data additional data coming indication real happy say doubled manufacturing capacity since beginning cell processing continuing work ghent facility secondary source supply brought contract manufacturer completely transformed expanded lentivirus production ratelimiting step u know flat roughly flat quarter quarter q q noted really phasing timing order actually delivered built nothing anything really see anticipate continued growth asset particularly second half versus first half continue add slot expand capacity based data everything seeing continued lot optimism carvykti performing likewise relates tecvayli tecvayli launch going well around world consistently seeing strong uptake rapid adoption whether yous germany austria france major market launched date really first believe bestinclass offtheshelf bcma bispecific really believe therapy offering deep durable response lot optimism continuing drive launch product performing well later line setting also performing well competitive standpoint last least actually talvey th product doubledigit growth although fall oncology category fully breaking yet strong uptake first gprcd offtheshelf bispecific well think really mean got fabulous opportunity across line therapy believe truly bestinclass agent many agent potential well combined work toward curing multiple myeloma significant business u positive outlook rest year going forwardoperatorthank next question coming larry biegelsen well fargo line livelarry biegelsen well fargo security analyst good morning thanks taking question question tim medtech business grew adjusted operational basis q number onetime item net impact onetime item view seeing around world procedure standpoint expectation rest year thank youtim schmid executive vice president worldwide chairman medtech well thank question larry let maybe reflect little journey know surpassed billion last year adjusted operational growth think important note compare majority competitor within competitive composite double size performance particularly proud followed another solid quarter growth first quarter larry point noise particularly proud tremendous doubledigit growth within electrophysiology business put context business nearing billion growing north think really called leadership position continuing build could excited progress making pfa believe also continue drive performance noise specifically relation vision business please rest assured extremely confident underlying health vision portfolio business grew last year expect grow high singledigit performance year stocking issue related distributor inventory predominant driver performance see year confident see return strong singledigit performance remainder year couple onetimers term selling day mentioned earlier bps selling day revenue recognition change within orthopaedics business impacted business basis point strong quarter larry remain committed strong high singledigit growth remainder year john reed executive vice president pharmaceutical research development larry want maybe add tims good comment onetimers tailwind headwind number seeing pretty much true number consider side equationoperatorour next question coming chris schott jp morgan line livechris schott jpmorgan chase company analyst great thanks much question bd question guess following shockwave acquisition appetite guess away maybe talk like larger tuckin type transaction either medtech pharma business seems like portfolio pipeline jj evolved pretty nicely past year interested think business point think maybe smaller earlierstage asset primary focus bd still greater sense urgency either medtech pharma add kind bolton type transaction going forwardjoaquin duato chairman chief executive officer thank chris joaquin glad recognize strategic consistency trajectory good strategy look long term going change capital allocation strategy continue disciplined going remain critical component important underline strength cash flow balance sheet significant flexibility consider multiple type transaction mentioned done far demonstration abiomed laminar ambrx planned acquisition shockwave good example studying consistency principle outlined going change strategy going change continue evaluate opportunity agnostic sector size looking number component one technology improve current standard care critical u extent believe patient impact positive number two consistent capability knowledge inhouse see correlation success acquisition number three enable u enter higher growth market area growing continue develop market finally important u continue deliver compelling financial result shareholder strategy cornerstone ability create value glad recognize consistency deployed going change looking future think think decade think opportunisticallyoperatorthank next question coming joanne wuensch citibank line livejoanne wuensch citi analyst good morning thank taking question circle back vision care please unpack different part positive negative iol contact lens businesstim schmid executive vice president worldwide chairman medtech course joanne thank bringing look odd certainly consistent expectation performance expect going forward business mentioned earlier business grew actually consistently grows high single digit absolutely believe underlying health vision business remains strong continues perform market mentioned earlier q performance predominantly driven contraction yous distributor inventory contact lens mentioned past variability term supply resulted change within distributor inventory started see supply contact lens stabilized started see normalization inventory distributor carrying hand big driver result see today know contact lens annuity business gain fair share new user time protecting base incredibly pleased ongoing performance premium acuvue oasys day family seeing unprecedented share gain multifocal also say look sequential share gain across contact lens business seeing sequential gain bode well continued performance remainder year specifically iol know currently market leader expecting deliver fourth consecutive year global share gain driven primarily tremendous performance iol business asiapac emea also excited heard jess earlier limited market release tecnis puresee odyssey nextgen multifocals see full release occur remainder year confident see tremendous improvement performance business expect high singledigit growth vision thank joanneoperatorthank next question coming chris shibutani goldman sachs line livechris shibutani goldman sachs analyst great thank much good morning could ask pulmonary hypertension business quarter quite strong mentioned particular share gain favorable patient mix could help u understand little bit better forward pulmonary arterial hypertension segment anticipated see disruption introduction recently approved product merck winrevair comment thinking portfolio perform market respond anticipated shift thank youjennifer taubert executive vice president worldwide chairman innovative medicine chris jennifer yes really pleased pulmonary hypertension result first quarter opsumit uptravi delivering strong growth volume share gain market well favorable patient mix really rounding year favorable patient mix last piece see continuing go forward degree product performing well patient pah importantly quarter got approval opsynvi first combination tablet pde era line guideline really patient diagnosed really right first choice start combination therapy think important introduction take look portfolio even despite new competitor coming believe opsumit uptravi got strong usage launch opsynvi well continue really productive asset good therapeutic area usoperatorthank next question coming danielle antalffy ubs line livedanielle antalffy ubs analyst hey good morning everyone thank much taking question tim could follow medtech specifically orthopaedics appreciate onetime revenue recognition sure provide color exactly changed also talked consistent medtech growth going forward mean taking backing get sort yous orthopaedic sale growth right way think specific segment going forward missing onetime tailwind maybe talk little bit outlook ortho given guy put quartertim schmid executive vice president worldwide chairman medtech thank danielle firstly operating robust market communicated fourth quarter last year still see remnant procedural backlog benefiting primarily orthopaedics business expect continue least first half mentioned overall performance orthopaedics impacted onetime change revenue recognition timing related yous business impact business basis point keep mind also impact fewer selling day disproportionately impacted ortho business bps proud ongoing progress making specifically area needed compete better specifically hip knee saw high singledigit growth first quarter specifically knee driven tremendous performance velys platform within two year market procedure seeing constant tailwind expand provision velys emea asiapac remainder year think expect continued improvement orthopaedics business remainder year continue build portfolio drive expansion across globeoperatorthank next question today coming geoff meacham bank america line livecharlie yang bank america merrill lynch analyst charlie yang geoff two question please know recent news regarding invega sustennaxeplion litigation tell u kind kind think term potential kind impact term timing next step second talk strong bladder cancer data expectation aua term kind benchmark expect term year cr rate thank youjennifer taubert executive vice president worldwide chairman innovative medicine perfect well take invega sustenna question pas colleague john take next one think lai portfolio longacting injectables reminder everybody really leading therapy space invega sustenna invega trinza invega hafyera product really excited latest data particularly hafyera recent study show two year patient humira excuse hafyera relapsefree really really striking get legal question really speculate impact ongoing litigation said remain really confident strength invega sustenna patent going continue defend intellectual property associated patent clear go little bit deeper federal circuit april st decision invalidate patent remanded case back new jersey district court one ruled favor originally likewise another ruling another case patent different company also go favor going back original judge ruled favor patent see come speculate remain really confident strength patentsjohn reed executive vice president pharmaceutical research development yes thanks interest platform drug device combo early bladder cancer clearly great unmet need much people every year diagnosed early bladder cancer vast majority patient go bladder removed clearly detrimental effect quality life drug device system think great example medtech pharma come together synergistic way delivered really think exciting early data presented esmo conference last september showed example tar product gemcitabine impressive complete response rate nice durability patient showed meeting still ongoing patient progress radical cystectomy think aua data yet disclosed provide detail think expect see longer followup patient expanded cohort believe track deliver pivotal data first indication bcg nonresponsive patient recollect early bladder nonmuscle invasive bladder cancer standard care attenuated mycobacteria bcg unfortunately fewer half patient receive achieve complete response therapy tolerability problem say least patient feel like chronic urinary tract infection discontinuation rate tar low delighted excellent tolerability profile well impressive deep efficacy deep durable efficacy yes please watch aua presentation think remain track filing early next year based pivotal data look forward sharing result congressoperatorthank next question coming matt miksic barclays line livematt miksic barclays analyst hi thanks much taking question followup maybe device trend particular cardio ep strong quarter wondering could provide color kind geographically product launch either driven overseas competitive environment yous affected yous performance far one quick one ortho couldtim schmid executive vice president worldwide chairman medtech sure matt firstly let start cardio joaquin mentioned made lot progress building portfolio recently participated one highgrowth category within cardiovascular electrophysiology touch performance second year lead electrophysiology built position cardiovascular acquisition abiomed year integrating business could proud progress made continue perform ahead deal model quarter growth excess give u two leadership position within cardiovascular care close acquisition shockwave third thoughtful deliberate move participate highgrowth highmargin cardiovascular area significant unmet need tremendous opportunity u grow excited fact one strategics high growth highmargin business largest category within medtech billion market growing roughly incremental billion growth coming category every year excited move specifically question ep seen growth across board excess yous exyous think really talk trust customer technology today rf portfolio rf product tested product year experience way going miss pfa progress made ensuring build presence category approval eu well japan also submitted fda approval control timing expect approval come end year early next year confident ability build leadership position ep specific question orthomatt miksic barclays analyst yes comment ortho generally sort low midsingle digit hip knee sounded like ish add back selling day double digit kind really chart growth think category wondering see sustainability rate ramping rate help u think rest year particular hip kneestim schmid executive vice president worldwide chairman medtech well matt think testament progress team within also building portfolio gap past filling gap hip even notably knee launch velys robot really creating tailwind enjoying today expect continue strong quarter see sort growth every single quarter absolutely sure expect high singledigit growth category going forward also say work done orthopaedics growth also improving margin profile know second quarter announced major restructuring focused really simplifying portfolio focusing business could drive greatest impact patient shareholder effort resulting reduction implant put context implant today within orthopaedics business real testament effort group drive topline performance also evolve portfolio improve margin thank mattjessica moore vice president investor relation thanks matt kevin time one questionoperatorthank final question today coming vamil divan guggenheim security line livevamil divan guggenheim partner analyst thanks much taking question one curious spravato sort strong growth quarter provide little context growth coming sort practice patient given product hopefully get sense trend question get lot investor drug price negotiation medicare drug selected year program ira know probably want get much specific curious share highlevel thought progress discussion going sort line expected anything sort different expected process play outjennifer taubert executive vice president worldwide chairman innovative medicine well thanks question thanks asking spravato continue really pleased uptake spravato continue launch product globally saw growth quarter continues perform well patient treatmentresistant depression got bold outlook spravato continue launch market able even penetrate existing market bit community setting term good really really good outlook also put plug neuroscience talk lot oncology business immunology business neuroscience also key area u spravato key platform also got aticaprant seltorexant coming mentioned longacting therapy invega sustenna franchise earlier back ira really clear think ira drug setting provision damaging healthcare innovative system something going help reinforce tremendous investment making rd develop next type treatment cure said focus patient access trying make sure product available patient need working appropriately government line process start going back forth around ultimate price round two going back forth still middle process really provide detail say product going process growth driver future product end life one going really key u coming year well end decade would love also reinforce remain confident got clear path achieving billion commitment made back december enterprise business review well delivering market growth compounded annual growth rate growth every year well year beyond irrespective ira take look growth driver pipeline coming feel real confident state businessjessica moore vice president investor relation thank vamil thanks everyone question continued interest company apologize could get time hesitate reach investor relation team remaining question may turn call joaquin brief closing remarksjoaquin duato chairman chief executive officer thank jess johnson johnson solid firstquarter performance reflects sharpened focus progress portfolio pipeline impact across full spectrum healthcare unique industry commercial clinical capital allocation milestone achieved q reinforce position innovation powerhouse one significant milestone quarter announcement planned acquisition shockwave strengthen leadership position cardiovascular continue make strong progress toward goal set december enterprise business review looking forward achieve remainder operatoroperator signoff duration minutescall participantsjessica moore vice president investor relationsjoe wolk executive vice president chief financial officerterence flynn morgan stanley analystjoaquin duato chairman chief executive officerjennifer taubert executive vice president worldwide chairman innovative medicinelarry biegelsen well fargo security analysttim schmid executive vice president worldwide chairman medtechjohn reed executive vice president pharmaceutical research developmentchris schott jpmorgan chase company analystjoanne wuensch citi analystchris shibutani goldman sachs analystdanielle antalffy ubs analystcharlie yang bank america merrill lynch analystmatt miksic barclays analystvamil divan guggenheim partner analyst jnj analysis earnings call transcript article transcript conference call produced motley fool strive foolish best may error omission inaccuracy transcript article motley fool assume responsibility use content strongly encourage research including listening call reading company sec filing please see term condition additional detail including obligatory capitalized disclaimer liabilitythe motley fool recommends johnson johnson motley fool disclosure policy